NCT07323368 Advancing Reperfusion Therapy for Ischemic Stroke: Perfusion-guided Endovascular Intervention for Medium Vessel Occlusion Therapy
| NCT ID | NCT07323368 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Stroke Ischemic |
| Study Type | INTERVENTIONAL |
| Enrollment | 568 participants |
| Start Date | 2026-02-08 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 568 participants in total. It began in 2026-02-08 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of perfusion-guided endovascular treatment (EVT) compared to standard medical care for patients with acute ischemic stroke due to medium vessel occlusion (MeVO) within 24 hours from symptom onset.
Eligibility Criteria
Inclusion Criteria: * Age≥18 years old; * Acute ischemic stroke symptom onset within 24 hours; including wake-up stroke and unwitnessed stroke, onset time refers to "last-seen normal time"; * Primary medium vessel occlusions confirmed by CTA/MRA, including non-dominant proximal M2 or mid-distal M2/M3 segments of the middle cerebral artery (MCA), A1/A2/A3 segments of the anterior cerebral artery (ACA), and P1/P2/P3 segments of the posterior cerebral artery (PCA) and responsible for the signs and symptoms of acute ischemic stroke; * Pre-stroke modified Rankin scale (mRS) score ≤1; * Baseline National Institutes of Health Stroke Scale (NIHSS) ≥8; * Neuroimaging criteria: Target mismatch profile on CT perfusion or MRI+MR perfusion (ischemic core volume \<70 mL, mismatch rate \>1.2, mismatch volume \>10 mL); * Written informed consent from patients or their legally authorized representatives. Exclusion Criteria: * Any evidence of intracranial hemorrhage on qualifying imaging; * Known (serious) sensitivity to radiographic contrast agents, nickel, titanium metals or their alloys and unable to complete CTP/PWI; * Known history of arterial tortuosity, pre-existing stent, other arterial disease and/or known disease at the arterial access site that would prevent the device from reaching the target vessel and/or preclude safe recovery after EVT; * Radiological confirmed evidence of mass effect or intracranial tumour (except small meningioma); * Clinical diagnosis of cerebral vasculitis; * Evidence of vessel recanalization prior to randomisation; * Severe comorbidities, which will likely prevent improvement or follow-up; * Any terminal illness such that the patient would not be expected to survive more than 1 year; * Hypodensity in \>1/3 MCA territory on non-contrast CT or significant hypodensity outside the current perfusion lesion suggesting distal clot migration (secondary MeVO); * Multiple arterial occlusion; * Pregnant women, nursing mothers, or reluctance to use effective contraceptive measures during the period of the trial; * Unlikely to adhere to the trial protocol or follow-up; * Participation in other interventional clinical trials within the previous 3 months.
Contact & Investigator
Yunyun Xiong, professor
PRINCIPAL INVESTIGATOR
Beijing Tiantan Hospital
Frequently Asked Questions
Who can join the NCT07323368 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke Ischemic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07323368 currently recruiting?
Yes, NCT07323368 is actively recruiting participants. Contact the research team at xiongyunyun@bjtth.org for enrollment information.
Where is the NCT07323368 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China, Longzhou, China, Luoyang, China and 2 additional locations.
Who is sponsoring the NCT07323368 clinical trial?
NCT07323368 is sponsored by Beijing Tiantan Hospital. The principal investigator is Yunyun Xiong, professor at Beijing Tiantan Hospital. The trial plans to enroll 568 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.